Werewolf Therapeutics, Inc.

NasdaqGS:HOWL

Market Cap

USD 48.46 M

Share Price

USD 1.08

Avg Daily Volume

504,261

Change (1 day)

0.94%

Change (1 year)

-50.91%

Change (YTD)

-27.03%

Werewolf Therapeutics, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending December 31, 2024: -3,487.53%

Werewolf Therapeutics, Inc. EBITDA Margin is -3,487.53% for the Trailing 12 Months (TTM) ending December 31, 2024, a 1,897.47% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Werewolf Therapeutics, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending December 31, 2023 was -174.60%, a -47.89% change year over year.
  • Werewolf Therapeutics, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending December 31, 2022 was -335.05%.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin